As of May 29, 2025, Kiadis Pharma NV (KDS.AS) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Kiadis Pharma NV's Forward P/E to Peers
To better understand Kiadis Pharma NV's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Kiadis Pharma NV (KDS.AS) | - |
| Bioventix PLC (BVXP.L) | 1858.44 |
| Oryzon Genomics SA (ORY.MC) | 150.74 |
| Pharming Group NV (PHARM.AS) | 53.43 |
| argenx SE (ARGX.BR) | 50.45 |
| Orphazyme A/S (ORPHA.CO) | 16.18 |
Compared to its competitors, Kiadis Pharma NV's Forward P/E is difficult to compare due to insufficient data.